Format
Items per page
Sort by

Send to:

Choose Destination

Results: 1 to 20 of 188

Similar articles for PubMed (Select 21435608)

1.

5-year follow-up of polytetrafluoroethylene-covered stents compared with bare-metal stents in aortocoronary saphenous vein grafts the randomized BARRICADE (barrier approach to restenosis: restrict intima to curtail adverse events) trial.

Stone GW, Goldberg S, O'Shaughnessy C, Midei M, Siegel RM, Cristea E, Dangas G, Lansky AJ, Mehran R.

JACC Cardiovasc Interv. 2011 Mar;4(3):300-9. doi: 10.1016/j.jcin.2010.11.013.

2.

Continued benefit from paclitaxel-eluting compared with bare-metal stent implantation in saphenous vein graft lesions during long-term follow-up of the SOS (Stenting of Saphenous Vein Grafts) trial.

Brilakis ES, Lichtenwalter C, Abdel-karim AR, de Lemos JA, Obel O, Addo T, Roesle M, Haagen D, Rangan BV, Saeed B, Bissett JK, Sachdeva R, Voudris VV, Karyofillis P, Kar B, Rossen J, Fasseas P, Berger P, Banerjee S.

JACC Cardiovasc Interv. 2011 Feb;4(2):176-82. doi: 10.1016/j.jcin.2010.10.003.

3.

Outcomes with drug-eluting versus bare-metal stents in saphenous vein graft intervention results from the STENT (strategic transcatheter evaluation of new therapies) group.

Brodie BR, Wilson H, Stuckey T, Nussbaum M, Laurent S, Bradshaw B, Humphrey A, Metzger C, Hermiller J, Krainin F, Juk S, Cheek B, Duffy P, Simonton CA; STENT Group.

JACC Cardiovasc Interv. 2009 Nov;2(11):1105-12. doi: 10.1016/j.jcin.2009.08.020.

4.

Clinical presentation and angiographic characteristics of saphenous vein graft failure after stenting: insights from the SOS (stenting of saphenous vein grafts) trial.

Lichtenwalter C, de Lemos JA, Roesle M, Obel O, Holper EM, Haagen D, Saeed B, Iturbe JM, Shunk K, Bissett JK, Sachdeva R, Voudris VV, Karyofillis P, Kar B, Rossen J, Fasseas P, Berger P, Banerjee S, Brilakis ES.

JACC Cardiovasc Interv. 2009 Sep;2(9):855-60. doi: 10.1016/j.jcin.2009.06.014.

5.

A randomized trial of polytetrafluoroethylene-membrane-covered stents compared with conventional stents in aortocoronary saphenous vein grafts.

Schächinger V, Hamm CW, Münzel T, Haude M, Baldus S, Grube E, Bonzel T, Konorza T, Köster R, Arnold R, Haase J, Probst P, vom Dahl J, Neumann FJ, Mudra H, Hennen B, Thiele L, Zeiher AM; STENTS (STents IN Grafts) Investigators.

J Am Coll Cardiol. 2003 Oct 15;42(8):1360-9.

6.

Outcomes after implantation of the TAXUS paclitaxel-eluting stent in saphenous vein graft lesions: results from the ARRIVE (TAXUS Peri-Approval Registry: A Multicenter Safety Surveillance) program.

Brilakis ES, Lasala JM, Cox DA, Berger PB, Bowman TS, Starzyk RM, Dawkins KD.

JACC Cardiovasc Interv. 2010 Jul;3(7):742-50. doi: 10.1016/j.jcin.2010.04.012.

7.

Comparison of long-term outcomes of drug-eluting stents and bare metal stents for saphenous vein graft stenosis.

Chakravarty T, Morrissey RP, Wertman B, Naghi J, Chou S, Goykhman P, Doctor N, Mirocha J, Forrester JS, Makkar R.

Catheter Cardiovasc Interv. 2012 May 1;79(6):903-9. doi: 10.1002/ccd.23187. Epub 2011 Jul 29.

PMID:
21805570
8.

Increased late mortality after sirolimus-eluting stents versus bare-metal stents in diseased saphenous vein grafts: results from the randomized DELAYED RRISC Trial.

Vermeersch P, Agostoni P, Verheye S, Van den Heuvel P, Convens C, Van den Branden F, Van Langenhove G; DELAYED RRISC (Death and Events at Long-term follow-up AnalYsis: Extended Duration of the Reduction of Restenosis In Saphenous vein grafts with Cypher stent) Investigators.

J Am Coll Cardiol. 2007 Jul 17;50(3):261-7. Epub 2007 Jun 13.

9.

Seven-year safety and efficacy of the unrestricted use of drug-eluting stents in saphenous vein bypass grafts.

Nauta ST, Van Mieghem NM, Magro M, Deckers JW, Simsek C, Van Geuns RJ, Van Der Giessen WJ, De Jaegere P, Regar E, Van Domburg RT, Serruys PW.

Catheter Cardiovasc Interv. 2012 May 1;79(6):912-8. doi: 10.1002/ccd.23145. Epub 2011 Nov 30.

PMID:
21542111
10.

In-hospital and 1-year outcomes with drug-eluting versus bare metal stents in saphenous vein graft intervention: a report from the EVENT registry.

Tolerico PH, Cohen DJ, Kleiman NS, Berger PB, Brilakis ES, Piana RN, Shammo S, Keyes MJ, Kennedy KF, Massaro JM, Saucedo JF; EVENT Investigators.

Catheter Cardiovasc Interv. 2012 Dec 1;80(7):1127-36. doi: 10.1002/ccd.24352. Epub 2012 May 4.

PMID:
22431166
11.

Randomized double-blind comparison of sirolimus-eluting stent versus bare-metal stent implantation in diseased saphenous vein grafts: six-month angiographic, intravascular ultrasound, and clinical follow-up of the RRISC Trial.

Vermeersch P, Agostoni P, Verheye S, Van den Heuvel P, Convens C, Bruining N, Van den Branden F, Van Langenhove G.

J Am Coll Cardiol. 2006 Dec 19;48(12):2423-31. Epub 2006 Nov 28.

12.

3-year follow-up of the SISR (Sirolimus-Eluting Stents Versus Vascular Brachytherapy for In-Stent Restenosis) trial.

Holmes DR Jr, Teirstein PS, Satler L, Sketch MH Jr, Popma JJ, Mauri L, Wang HP, Schleckser PA, Cohen SA; SISR Investigators.

JACC Cardiovasc Interv. 2008 Aug;1(4):439-48. doi: 10.1016/j.jcin.2008.05.010.

13.

Long term follow-up of drug eluting versus bare metal stents in the treatment of saphenous vein graft lesions.

Ybarra LF, Ribeiro HB, Pozetti AH, Campos CA, Esper RB, Lemos PA, Lopes AC, Kalil-Filho R, Ellis SG, Ribeiro EE.

Catheter Cardiovasc Interv. 2013 Dec 1;82(7):E856-63. doi: 10.1002/ccd.24781. Epub 2013 Aug 1.

PMID:
23239630
14.

Long-term outcomes of drug-eluting stents versus bare-metal stents in saphenous vein graft disease: results from the Prairie "Real World" Stent Registry.

Goswami NJ, Gaffigan M, Berrio G, Plessa AL, Pfeiffer AM, Markwell SJ, Mishkel GJ.

Catheter Cardiovasc Interv. 2010 Jan 1;75(1):93-100. doi: 10.1002/ccd.22194.

PMID:
19787803
15.

A randomized controlled trial of a paclitaxel-eluting stent versus a similar bare-metal stent in saphenous vein graft lesions the SOS (Stenting of Saphenous Vein Grafts) trial.

Brilakis ES, Lichtenwalter C, de Lemos JA, Roesle M, Obel O, Haagen D, Saeed B, Gadiparthi C, Bissett JK, Sachdeva R, Voudris VV, Karyofillis P, Kar B, Rossen J, Fasseas P, Berger P, Banerjee S.

J Am Coll Cardiol. 2009 Mar 17;53(11):919-28. doi: 10.1016/j.jacc.2008.11.029.

16.

Drug-eluting stents versus bare-metal stents for treatment of bare-metal in-stent restenosis.

Singh IM, Filby SJ, El Sakr F, Gorodeski EZ, Lincoff AM, Ellis SG, Shishehbor MH.

Catheter Cardiovasc Interv. 2010 Aug 1;76(2):257-62. doi: 10.1002/ccd.22509.

17.

Randomized evaluation of polytetrafluoroethylene-covered stent in saphenous vein grafts: the Randomized Evaluation of polytetrafluoroethylene COVERed stent in Saphenous vein grafts (RECOVERS) Trial.

Stankovic G, Colombo A, Presbitero P, van den Branden F, Inglese L, Cernigliaro C, Niccoli L, Bartorelli AL, Rubartelli P, Reifart N, Heyndrickx GR, Saunamäki K, Morice MC, Sgura FA, Di Mario C; Randomized Evaluation of polytetrafluoroethylene COVERed stent in Saphenous vein grafts investigators.

Circulation. 2003 Jul 8;108(1):37-42. Epub 2003 Jun 23.

18.

Comparison of the slow-release polymer-based paclitaxel-eluting Taxus-Express stent with the bare-metal Express stent for saphenous vein graft interventions.

Wöhrle J, Nusser T, Kestler HA, Kochs M, Hombach V.

Clin Res Cardiol. 2007 Feb;96(2):70-6. Epub 2006 Dec 8.

PMID:
17146605
19.

Pathology of drug-eluting versus bare-metal stents in saphenous vein bypass graft lesions.

Yazdani SK, Farb A, Nakano M, Vorpahl M, Ladich E, Finn AV, Kolodgie FD, Virmani R.

JACC Cardiovasc Interv. 2012 Jun;5(6):666-74. doi: 10.1016/j.jcin.2011.12.017.

20.

Angiographic and clinical outcomes of drug-eluting versus bare metal stent deployment in the Occluded Artery Trial.

Dzavík V, Buller CE, Devlin G, Carere RG, Mancini GB, Cantor WJ, Buszman PE, Rankin JM, Vozzi C, Ross JR, Forman S, Barton BA, Lamas AG, Hochman JS.

Catheter Cardiovasc Interv. 2009 May 1;73(6):771-9. doi: 10.1002/ccd.21930.

Format
Items per page
Sort by

Send to:

Choose Destination

Supplemental Content

Write to the Help Desk